BridgeBio Pharma Secures $200M Private Financing to Propel Oncology Portfolio Development

Palo Alto, CA, May 2, 2024 (Globe Newswire) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) recently completed a $200M private financing round for its former subsidiary, TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT), aiming to strengthen its oncology portfolio. Led by Cormorant Asset Management and co-led by Omega Funds, the oversubscribed financing reflects confidence from investors like Deerfield Management, GV, EcoR1 Capital, and others. This funding infusion is intended to accelerate BridgeBio's oncology initiatives, furthering its mission to address genetic diseases and cancers.

Read full article here.